Reuters logo
3 个月内
BRIEF-Acceleron says enrolment for late stage studies now expected to be completed in Q2
2017年4月27日 / 下午12点39分 / 3 个月内

BRIEF-Acceleron says enrolment for late stage studies now expected to be completed in Q2

1 分钟阅读

April 27 (Reuters) - Acceleron Pharma Inc

* Acceleron provides clinical development updates on luspatercept program

* Acceleron pharma inc says enrollment in MEDALIST and BELIEVE phase 3 studies now expected to be completed in q2 2017

* "we now look forward to reporting topline results from medalist and believe phase 3 studies in mid-2018"

* Acceleron pharma inc says acceleron and celgene also plan to initiate a third phase 3 trial of luspatercept

* New phase 3 trial of luspatercept is expected to be initiated in early 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below